(61) demonstrated that hypoxia and hypoxia-driven angiogenesis have an important role in the recurrence of HCC after RFA and that sorafenib is an effective inhibitor of the HIF-1a/VEGFA pathway. This evidence concerns the gene HIF1A and hepatocellular carcinoma.